Rizwana F. Sproule, VP Regulatory Affairs at Kite Pharma, Inc. (KITE), sold 9,567 shares at $65.38 ($610K) on 2015-12-15, disclosed to the SEC on 2015-12-17.
Scheduled sale ($610k) by VP Regulatory Affairs under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $62.70 | 3,373 | $211K | 34.7% |
| 2 | $63.73 | 2,410 | $154K | 25.2% |
| 3 | $64.64 | 3,352 | $217K | 35.5% |
| 4 | $65.38 | 432 | $28K | 4.6% |
| Total | $63.76 avg | 9,567 | $610K | 100% |
| Filing → |
| KITE | SELL | 2016-01-19 | $531K | — | Filing → |
| KITE | SELL | 2015-11-18 | $748K | — | Filing → |
| KITE | SELL | 2015-10-19 | $599K | — | Filing → |